Cathie Wood’s ARK sees major buys in Robinhood stock, trims Teradyne

ARK disclosed a $12,744,688 purchase of 182,641 Robinhood (HOOD) shares across ARKK/ARKW/ARKF on April 7, 2026, its largest trade that day. Other notable moves: sold 9,481 Teradyne (TER) for $2,990,591 (continuing a recent trim), bought 6,944 Tesla (TSLA) for $2,449,982, sold 60,093 Twist Bioscience (TWST) for $3,075,559, sold 26,838 Roku (ROKU) for $2,635,491, trimmed Intercontinental Exchange (ICE) by 6,900 shares ($1,148,091), bought 4,121 GeneDx (WGS) for $274,499 and bought 7,244 Kodiak AI (KDK) for $54,619. These trades indicate ARK is rotating capital toward fintech, AI and EV exposure while trimming several tech/biotech positions; market impact should be limited to idiosyncratic moves in smaller-cap names.

Analysis

ETF-driven concentration into a handful of retail/AI/EV names has become a self-reinforcing liquidity axis: short-term skew and realized vol distortions amplify price moves, which then attract more algorithmic and retail flow. For mid-cap names this can translate into 3–7% directional moves and 15–30% intraday option-skew swings from a single large ETF rebalancing or buy/sell wave, creating predictable liquidity-to-volatility arbitrage windows on 1–10 day horizons.

Exchange and market-structure exposures (ICE-style business models) sit on the opposite side of that delivery: more retail execution skews clearing and custody volumes but can compress per-trade revenues if pricing/competitive dynamics shift. The real catalyst set that will reverse the current pattern is not macro alone — it’s a combination of: concentrated ETF de-risking (weeks), regulatory changes to retail order routing or payment-for-order-flow (months), or a pronounced re-rating of tech/AI adoption curves (quarters to years).

Second-order winners are niche service providers that monetize elevated retail churn (clearing, custody, options market-makers) while losers are incumbent exchanges if fee pressure or best-execution regulation intensifies. The consensus underestimates persistence of flow-driven alpha but overestimates structural “exchange death” — exchanges have stickier data/clearing revenue than people credit, so the optimal trades are asymmetric conditional on a 2–6 month regulatory/flow outcome rather than binary long-only bets.

Key Decisions for Investors

• Long HOOD via a defined-risk call-spread (buy 12–18 month ITM call / sell further OTM call to fund ~50–70% of premium). Size 1–2% portfolio; target 40–80% upside if retail-led multiple expansion continues within 9–18 months; stop if price falls 20% from entry or implied vol normalizes downward by 25% post-entry.
• Relative pair: long HOOD / short ICE equal-dollar for 3–6 months to capture flow-driven platform outperformance vs exchange fee-compression risk. Target 15–25% relative return; initial stop-loss if the spread moves against us by 8–10%; trim half at +8% relative gain.
• Volatility capture on EV/AI leaders (e.g., TSLA exposure) — sell 30-day calls against long-dated calls or shares to monetize gamma while maintaining directional upside. Use a 3–6 month cadence to harvest elevated short-term premia; cap allocation at 1–2% and avoid during earnings windows.
• Tactical short/option-skew trade in small biotech names without near-term cash runway: buy 3–9 month put spreads on microcaps where retail-driven bid can evaporate quickly. Keep position sizes small (<=0.5% each) and target 2–4x premium if clinical/regulatory disappointment or flow reversal occurs.